1. Home
  2. ZJYL vs ITOS Comparison

ZJYL vs ITOS Comparison

Compare ZJYL & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZJYL
  • ITOS
  • Stock Information
  • Founded
  • ZJYL 2006
  • ITOS 2011
  • Country
  • ZJYL China
  • ITOS United States
  • Employees
  • ZJYL N/A
  • ITOS N/A
  • Industry
  • ZJYL Industrial Specialties
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ZJYL Consumer Discretionary
  • ITOS Health Care
  • Exchange
  • ZJYL Nasdaq
  • ITOS Nasdaq
  • Market Cap
  • ZJYL N/A
  • ITOS 381.2M
  • IPO Year
  • ZJYL 2023
  • ITOS 2020
  • Fundamental
  • Price
  • ZJYL $0.65
  • ITOS $9.99
  • Analyst Decision
  • ZJYL
  • ITOS Hold
  • Analyst Count
  • ZJYL 0
  • ITOS 6
  • Target Price
  • ZJYL N/A
  • ITOS $10.60
  • AVG Volume (30 Days)
  • ZJYL 194.2K
  • ITOS 1.0M
  • Earning Date
  • ZJYL 07-25-2025
  • ITOS 08-07-2025
  • Dividend Yield
  • ZJYL N/A
  • ITOS N/A
  • EPS Growth
  • ZJYL 18.46
  • ITOS N/A
  • EPS
  • ZJYL 0.02
  • ITOS N/A
  • Revenue
  • ZJYL $23,502,010.00
  • ITOS $35,000,000.00
  • Revenue This Year
  • ZJYL N/A
  • ITOS N/A
  • Revenue Next Year
  • ZJYL N/A
  • ITOS N/A
  • P/E Ratio
  • ZJYL $27.66
  • ITOS N/A
  • Revenue Growth
  • ZJYL 18.57
  • ITOS 177.89
  • 52 Week Low
  • ZJYL $0.56
  • ITOS $4.80
  • 52 Week High
  • ZJYL $4.38
  • ITOS $18.13
  • Technical
  • Relative Strength Index (RSI)
  • ZJYL 41.76
  • ITOS 62.26
  • Support Level
  • ZJYL $0.61
  • ITOS $9.91
  • Resistance Level
  • ZJYL $0.71
  • ITOS $10.20
  • Average True Range (ATR)
  • ZJYL 0.05
  • ITOS 0.16
  • MACD
  • ZJYL -0.00
  • ITOS -0.12
  • Stochastic Oscillator
  • ZJYL 37.72
  • ITOS 13.56

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Share on Social Networks: